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Rotavirus P[4]G2 
in a Vaccinated 
Population, Brazil
To the Editor: Gurgel et al. pro-
vide an early examination of postmar-
keting surveillance data from Brazil, 
one of the ? rst countries to implement 
routine childhood immunization with 
Rotarix vaccine (1). In a community 
with reported vaccination coverage of 
50%, the P[4]G2 strain was detected in 
all 21 rotavirus-positive stool samples 
identi? ed  during  November  2006–
February 2007. Although monitoring 
effectiveness of Rotarix against P[4]
G2 strains is of interest (2), the small 
sample size, short duration of surveil-
lance, and lack of a comparison group 
preclude ? rm assessment of an asso-
ciation between P[4]G2 predominance 
and vaccination.
Because Rotarix was introduced 
in Brazil in March 2006, most children 
>12 months old (66 [51%] of 129) in 
the study were ineligible for vaccina-
tion. Genotype P[4]G2 was the only 
strain identi? ed even in older children, 
which suggests either a change in dis-
ease ecology from vaccination or the 
random circulation of P[4]G2 strains 
in the community. Ongoing hospital-
based  surveillance  during  2006  in  3 
regional countries that had not intro-
duced rotavirus vaccine (El Salvador, 
Guatemala,  and  Honduras)  showed 
that P[4]G2 was the predominant cir-
culating strain (prevalence 68%–81%). 
Thus, as previously documented (3,4),
the  predominance  of  P[4]G2  strains 
after  Rotarix  introduction  in  Brazil 
could  represent  a  natural  shift  unre-
lated to vaccination.
Evaluation  of  vaccine  effective-
ness against speci? c strains will allow 
full  assessment  of  the  public  health 
impact  of  vaccination. Although  the 
data are sparse in the study from Gur-
gel et al., a comparison of the odds of 
vaccination among rotavirus-positive 
(cases)  versus  rotavirus-negative 
(controls)  children  shows  80%  vac-
cine  effectiveness  against  P[4]G2 
strains among infants <1 year of age, 
in accordance with recently published 
data  from  a  controlled  trial  (5).  To 
further elucidate vaccine impact, we 
are providing support for vaccine ef-
fectiveness studies in Nicaragua and 
El  Salvador  and  conducting  strain 
monitoring before and after licensure 
throughout Latin America.
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To the Editor: Gurgel et al. de-
scribed the predominance of P[4]G2 
rotaviruses in a vaccinated population 
in  Aracaju,  northeastern  Brazil  (1).
However, several limitations need to 
be addressed to avoid misinterpreta-
tion of data that could lead to loss of 
con? dence in the vaccine in Brazil and 
other countries.
Brazil was one of the ? rst coun-
tries in Latin America to introduce a 
live, oral, attenuated human rotavirus 
vaccine  into  a  public-sector  health 
program.  Nevertheless,  vaccine  cov-
erage levels vary considerably across 
regions  (≈40%  to  >80%)  and  are 
≈50% in some parts of northern and 
northeastern Brazil. Therefore, draw-
ing  conclusions  about  the  vaccine’s 
protection  and  prevailing  rotavirus 
genotypes in a setting where coverage 
is still low seems premature.
Two ? ndings require special con-
sideration. First, although the number 
of patients is small, children <1 year of 
age showed a reduced risk for severe 
rotavirus  diarrhea  among  vaccinated 
(7%) patients compared with nonvac-
cinated (26%) patients: p<0.05; odds 
ratio (OR) 0.20; exact 95% con? dence 
interval (CI) 0.029–1.24. Second, sur-
veillance  was  conducted  for  only  4 
months, which did not allow for dem-
onstration of a true representative pat-
tern  of  strain  distribution  over  time. 
The  sequential  changing  predomi-
nance of rotavirus serotypes occurring 
over time has been well documented 
for many years (2).
The authors stated that the “vac-
cine does not afford complete protec-
tion against infection” (1). For those 
not  paying  close  attention  to  data 
analysis, this statement could be mis-
interpreted to mean that the vaccine 
may not protect against P[4]G2. To the 
contrary, even with a small sample size 
and low vaccine coverage, additional 
analyses of the original data show that 
the live, oral, attenuated human rota-
virus vaccine can protect against the 
100% predominance of P[4]G2.
In a large phase III trial conducted in 
Latin America and Finland, a nonsig-
ni? cant but protective trend was ob-
served against severe disease associ-
ated with P[4]G2 (3). Furthermore, in 
a subsequent meta-analysis, protection 
against P[4]G2 rotavirus gastroenteri-
tis of any severity was 81% (95% CI 
31–96) and protection against severe 
rotavirus  gastroenteritis  was  71% 
(95% CI 20–91) (4).
To  reinforce  the  hypothesis  that 
predominance  of  P[4]G2  strains  in 
Aracaju is unrelated to vaccine use, it 
is worth mentioning that P[4]G2 rota-
viruses appear to display an ≈10-year
cyclic pattern of occurrence in Brazil 
(5).  Although  the  data  presented  in 
the original article may cause misin-
terpretation about vaccine protection, 
the  article  highlights  the  need  for 
well-designed  postmarketing  stud-
ies to assess both vaccine impact and 
strain surveillance, in compliance with 
recent World Health Organization rec-
ommendations (6).
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In  Response:  We  acknowledge 
the comments by Patel et al. (1) and 
by Linhares and Velázquez (2) about 
our article that documented the pres-
ence  of  a  single  rotavirus  genotype 
(P[4]G2) in Aracaju, northeastern Bra-
zil, after the introduction of a human, 
monovalent  rotavirus  vaccine  (3).
Both  letters  emphasize  that  the  pre-
dominance of P[4]G2 may be caused 
by  a  natural  genotype  variation  un-
related to vaccination. We agree that 
our observation could be explained by 
natural  variation  of  circulating  rota-
virus genotypes in the region, but an 
alternative possibility is that the intro-
duction of the G1P[8] rotavirus vac-
cine into the childhood immunization 
schedule created conditions in which 
P[4]G2 strains had a selective advan-
tage over strains with which the vac-
cine shares G type, P type, or both.
According to a systematic review 
of rotavirus genotypes reported in the 
25  years  preceding  introduction  of 
the vaccine in Brazil, the prevalence 
of  P[4]G2  strains  varied  from  19% 
(1986–1995) to 12% (1996–2000) to 
1%  thereafter,  thus  not  reaching  the 
detection rate we observed in Aracaju 
(R.Q. Gurgel et al., unpub data). Fur-
thermore, in the ensuing 8-month peri-
od, no genotype other than P[4]G2 had 
been detected in Aracaju, suggesting 
that our initial ? ndings were not spuri-
ous (R.Q. Gurgel et al., unpub data). In 
addition, in a separate study we con-
ducted in Recife, a city 500 km north 
of Aracaju, we observed a signi? cant 
increase in the proportion of G2 strains 
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detected from 47% (21/45) during the 
3-month period immediately after vac-
cine  introduction  (March  2006–May 
2006) to 100% (11/11) during the same 
3-month period 1 year after the vac-
cine  introduction  (March  2007–May 
2007) (4). We believe that our ? ndings 
are consistent with results of ? eld trials 
that indicated that the vaccine provided 
relatively less protection against P[4]
G2 strains than against other rotavirus 
strain types (5).
The bene? cial impact of rotavirus 
vaccination  in  northeastern  Brazil  is 
re? ected in the reduction of the detec-
tion  rate  of  rotavirus  among  severe 
diarrhea cases in our study in Recife, 
which fell from 27% (45/166 cases) to 
5.0%  (11/221  cases)  in  the  postvac-
cine  3-month  reporting  periods,  re-
spectively (4). Our data from Aracaju 
are  indicative  of  heterotypic  protec-
tion, although this is not statistically 
signi? cant (1), against P[4]G2 strains. 
Further postlicensure studies in Brazil 
are required to document continuing 
effectiveness  of  the  national  vacci-
nation program as well as to closely 
monitor the circulating rotavirus strain 
types (6).
Ricardo Queiroz Gurgel,*† 
Sarah Cristina Fontes Vieira,* 
Vanessa Cristiane Farias 
Barros,* Paula Brandão 
Fontes,*Eduardo F. Salustino,* 
Osamu Nakagomi,‡ 
Toyoko Nakagomi,‡ 
Winifred Dove,† 
Nigel A. Cunliffe,† 
and Luis E. Cuevas†§
*Federal  University  of  Sergipe,  Aracaju, 
Brazil; †University of Liverpool, Liverpool, 
UK;  ‡Nagasaki  University,  Nagasaki,  Ja-
pan;  and  §Liverpool  School  of  Tropical 
Medicine, Liverpool, UK
References
  1.   Patel  MM,  de  Oliveira  LH,  Bispo AM, 
Gentsch J, Parashar UD. Rotavirus P[4]
G2 in a vaccinated population, Brazil [let-
ter]. Emerg Infect Dis. 2008;14:863.
  2.   Linhares  AC,  Velázquez  FR.  Rotavirus 
P[4]G2 in a vaccinated population, Brazil 
[letter]. Emerg Infect Dis. 2008;14:864.
  3.   Gurgel RQ, Cuevas LE, Vieira SCF, Bar-
ros VCF, Fontes PB, Salustino ET, et al. 
Predominance  of  rotavirus  P[4]G2  in  a 
vaccinated population, Brazil. Emerg In-
fect Dis. 2007;13:1571–3.
  4.   Nakagomi T, Cuevas LE, Gurgel RQ, El-
rokhsi SH, Belkhir YA, Abugalia M, et al. 
Apparent extinction of non-G2 rotavirus 
strains from circulation in Recife, Brazil, 
after the introduction of rotavirus vaccine. 
Arch Virol. 2008;153:591–3.
  5.   Ruiz-Palacios  GM,  Perez-Schael  I,  Ve-
lazquez FR, Abate H, Breuer T, Clemens 
SC, et al. Safety and ef? cacy of an attenu-
ated vaccine against severe rotavirus gas-
troenteritis. N Engl J Med. 2006;354:11–
22.
  6.   Rotavirus vaccines. Wkly Epidemiol Rec. 
2007;82:285–96.
Address  for  correspondence:  Ricardo  Gurgel, 
Federal  University  of  Sergipe-Medicine  Post 
Graduation Nucleus, Rua Claudio Batista S/N 
Bairro Sanatorio, Aracaju Sergipe 49000 100, 
Brazil; email: ricardoqg@infonet.com.br
  5 6 8   8 0 0 2   y a M   , 5   . o N   , 4 1   . l o V   •   d i e / v o g . c d c . w w w   •   s e s a e s i D   s u o i t c e f n I   g n i g r e m E  
Erratum: Vol. 14, No. 4 
In the article “Reassortant Avian In? uenza Virus (H5N1) in Poultry, Nigeria, 2007” by I. Monne et al., the author 
af? liations contained errors. Isabella Monne, Tony M. Joannis, Alice Fusaro, Paola De Benedictis, Giovanni Cattoli, 
and Ilaria Capua are af? liated with Istituto Zoopro? lattico Sperimentale delle Venezie, Legnaro, Padova, Italy. 
We regret any confusion this error may have caused. 
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